News Search Results
Nov 17, 2025, 09:26 ET Breakthrough Properties Raises $430 Million to Propel Next Phase of Growth
around the world and support scientific innovation across biotechnology, agriculture, and nutrition. Breakthrough combines Tishman Speyer's decades of global real estate development experience with Bellco Capital's industry-making biotechnology entrepreneurship to reimagine environments where companies
More news about: Breakthrough Properties
Nov 17, 2025, 09:16 ET MLTX DEADLINE REMINDER: Berger Montague Reminds MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors of Important Class Action Lawsuit Deadline
CLICK HERE . MoonLake is a clinical-stage biotechnology company headquartered in Zug, Switzerland. According to the lawsuit, MoonLake and certain executives made false and misleading
More news about: Berger Montague
Nov 17, 2025, 09:15 ET Bambusa Therapeutics Announces Completion of Series A-2 Financing to Accelerate Next-Generation Bispecific Programs
BOSTON, Nov. 17, 2025 /PRNewswire/ -- Bambusa Therapeutics, Inc. ("Bambusa"), a clinical-stage biotechnology company pioneering next-generation bispecific antibodies for immunology and inflammation (I&I), today announced the completion of its oversubscribed
More news about: Bambusa Therapeutics, Inc.
Nov 17, 2025, 09:00 ET Breakthrough Properties Raises $430 Million to Propel Next Phase of Growth
around the world and support scientific innovation across biotechnology, agriculture, and nutrition. Breakthrough combines Tishman Speyer's decades of global real estate development experience with Bellco Capital's industry-making biotechnology entrepreneurship to reimagine environments where companies
More news about: Breakthrough Properties
Nov 17, 2025, 08:56 ET Oramed Reports Fiscal Third Quarter 2025 Financial Results
clinical trials and product development programs; difficulties or delays in obtaining regulatory approval; competition from other pharmaceutical or biotechnology companies; market volatility affecting our investment portfolio; our ability to realize expected returns from Scilex and other investments; and
More news about: Oramed Pharmaceuticals Inc.
Nov 17, 2025, 08:50 ET ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS
clinical trials and product development programs; difficulties or delays in obtaining regulatory approval; competition from other pharmaceutical or biotechnology companies; market volatility affecting our investment portfolio; our ability to realize expected returns from Scilex and other investments; and
More news about: Oramed Pharmaceuticals Inc.
Nov 17, 2025, 08:15 ET Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the International Nonproprietary Names (INN) Expert Committee of
More news about: Anixa Biosciences, Inc.
Nov 17, 2025, 08:05 ET Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology
Calif., Nov. 17, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced a peer-reviewed publication in the Journal of Hematology & Oncology
More news about: Rigel Pharmaceuticals, Inc.
Nov 17, 2025, 08:01 ET TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer
specializing in strategic support and portfolio management for early-stage pharmaceutical development. Through JMi ONConsulting, he has advised leading biotechnology companies in Europe and the U.S. on oncology R&D, preclinical and clinical strategy, and business development initiatives. He also co-founded
More news about: TransCode Therapeutics, Inc.
Nov 17, 2025, 07:00 ET NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute
NewcelX Ltd. (Nasdaq: NCEL) ("NewcelX" or "the Company"), a clinical-stage biotechnology company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, today announced the appointment of Prof.
More news about: NewcelX Ltd.
Nov 17, 2025, 07:00 ET Nanoscope Therapeutics Featured in Multiple Presentations at Advanced Therapies USA 2025
Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment
More news about: Nanoscope Therapeutics
Nov 17, 2025, 07:00 ET Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab
one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and
More news about: Halozyme Therapeutics, Inc.
Nov 17, 2025, 05:36 ET Stars of Science: Celebrating 17 Seasons of Innovators Driving the Region's Scientific Future
that estimates Vitamin D levels in the body and helps prevent mental health symptoms, won public voting and impressed judges for its fusion of biotechnology with emotional well-being. "Stars of Science transformed my journey - I turned pain into hope
More news about: Stars of Science
Nov 15, 2025, 11:00 ET BrainXell Showcases Pioneering iPSC Research and Promising In Vivo Data for BXT-110 for Parkinson's Disease at the 2025 Society for Neuroscience Annual Meeting
neurodegenerative disorders. Dr. Su-Chun Zhang, BrainXell Founder and Advising CSO, states, "BrainXell is at the forefront of the biotechnology industry, engineering novel cellular platforms for biomedical discovery and pharmaceutical development, as well as developing personalized regenerative
More news about: BrainXell, Inc
Nov 14, 2025, 11:10 ET OSR Holdings Appoints Scientific Co-Founder Dr. Andreas Niethammer as Chief Executive Officer of Vaximm AG to Lead Next Phase of Immuno-Oncology Expansion
About Vaximm AG Vaximm AG is a privately held Swiss-German biotechnology company and a subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH). Vaximm's proprietary oral T-cell vaccination platform harnesses live, attenuated
More news about: OSR Holdings
Nov 14, 2025, 10:30 ET AI in Biotechnology Market worth $22,716.5 million by 2035 with 18.5% CAGR | MarketsandMarkets™.
end-to-end solutions segment accounted for the largest share of the AI in biotechnology market, driven by the rising demand for integrated platforms that combine data management, analytics, and automation across the entire biotechnology workflow. These solutions enable seamless collaboration between research
More news about: MarketsandMarkets
Nov 14, 2025, 09:26 ET Curis to Present at Upcoming 30th Annual SNO Meeting
LEXINGTON, Mass., Nov. 14, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that Curis will
More news about: Curis, Inc.
Nov 14, 2025, 08:53 ET SAS Clinical Acceleration debuts to modernize clinical trials and accelerate time to market
N.C., Nov. 14, 2025 /PRNewswire/ -- In today's rapidly evolving health care landscape, pharmaceutical and biotechnology companies face mounting pressure to accelerate drug development while maintaining rigorous compliance with global regulatory standards. And the
More news about: SAS
Nov 14, 2025, 08:00 ET ETHZilla Reports Third Quarter 2025 Financial Results
: Successfully resolved all outstanding litigation against the legacy company, 180 Life Sciences, and divested the legacy biotechnology assets. The Company continues to retain the previously acquired iGaming assets until the physical assets associated with the tokenization
More news about: ETHZilla Corporation
Nov 14, 2025, 07:00 ET Lupin Launches Risperidone Long-Acting Injectable with 180-day CGT exclusivity in the U.S., the First Product from its Proprietary Long-Acting Injectable Platform PrecisionSphere™
products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position
More news about: Lupin Limited
Nov 14, 2025, 06:24 ET A KHB apresenta o FOCUS PEGASUS MF200 aprimorado -- redefinindo a eficiência em diagnósticos veterinários
XI'AN, China, 14 de novembro de 2025 /PRNewswire/ -- A Guangzhou Focus Biotechnology Co., Ltd., subsidiária do KHB Group e inovadora em soluções de testes veterinários no local de atendimento (POCT), apresenta o aprimorado Analisador
More news about: Shanghai Kehua Bio-engineering Co., Ltd.
Nov 14, 2025, 06:22 ET KHB presenta el FOCUS PEGASUS MF200 mejorado: una redefinición de la eficacia en el diagnóstico veterinario
XI'AN, China, 14 de noviembre de 2025 /PRNewswire/ -- Guangzhou Focus Biotechnology Co., Ltd., una filial de KHB Group e innovadora en soluciones de pruebas veterinarias en el punto de atención (POCT), presenta el analizador veterinario
More news about: Shanghai Kehua Bio-engineering Co., Ltd.
Nov 14, 2025, 06:19 ET KHB präsentiert verbesserten FOCUS PEGASUS MF200 - die Neudefinition von Effizienz in der Veterinärdiagnostik
XI'AN, China, 14. November 2025 /PRNewswire/ -- Guangzhou Focus Biotechnology Co., Ltd, eine Tochtergesellschaft der KHB Group und ein Innovator im Bereich der veterinärmedizinischen Point-of-Care-Tests (POCT), präsentiert
More news about: Shanghai Kehua Bio-engineering Co., Ltd.
Nov 14, 2025, 06:15 ET KHB présente le FOCUS PEGASUS MF200 amélioré - Redéfinir l'efficacité du diagnostic vétérinaire
XI'AN, Chine, 14 novembre 2025 14 novembre 2025 /PRNewswire/ -- Guangzhou Focus Biotechnology Co. Ltd, filiale du groupe KHB et innovateur en matière de solutions de tests vétérinaires sur le lieu de soins (POCT), présente l'analyseur vétérinaire
More news about: Shanghai Kehua Bio-engineering Co., Ltd.
Nov 14, 2025, 03:00 ET Medicxi Announces €500 Million Fund V
life sciences venture capital firm, today announced the closing of Medicxi V, a €500 million fund dedicated to building and backing innovative biotechnology companies with clear product visions to transform patient care. The oversubscribed fund closed with strong support from existing limited partners
More news about: Medicxi